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Key Points 30 
 Among patients with subclinical hypothyroidism, is the use of thyroid hormone therapy 31 
associated with improvements in general quality of life or thyroid-related symptoms? 32 
 In this meta-analysis of 21 randomized clinical trials  including 2,192 participants with 33 
subclinical hypothyroidism, thyroid hormone therapy was not significantly associated with 34 
improvements in general quality of life (standardized mean difference [SMD], -0.11) or thyroid-35 
related symptoms (SMD, 0.01).  36 
 These findings do not support the routine use of thyroid hormone therapy in adults with 37 
subclinical hypothyroidism. 38 
 39 
Abstract 40 
Importance: The benefit of thyroid hormone therapy for subclinical hypothyroidism is uncertain. New 41 
evidence from recent large randomized clinical trials (RCT) warrants an update of previous meta-42 
analyses. 43 
Objective: To conduct a meta-analysis of the association of thyroid hormone therapy with quality of 44 
life and thyroid related symptoms in adults with subclinical hypothyroidism. 45 
Data Sources: PubMed, Embase, clinicaltrials.gov, Web of Science, COCHRANE Library, CENTRAL, 46 
Emcare and Academic Search Premier from inception until July 4, 2018. 47 
Study Selection: RCTs that compared thyroid hormone therapy to placebo/no therapy in non-48 
pregnant adults with subclinical hypothyroidism were eligible. Two reviewers independently evaluated 49 
eligibility based on titles and abstracts of all retrieved studies. Studies not excluded in this first step 50 
were independently assessed for inclusion after full-text evaluation by two reviewers. 51 
Data Extraction and Synthesis: Two independent reviewers extracted data, assessed risk of bias 52 
(Cochrane risk of bias tool), and evaluated the quality of evidence (GRADE tool). For synthesis, 53 
differences in clinical scores were transformed (e.g. quality of life) into standardized mean differences 54 
(SMD, positive values indicate benefit of thyroid hormone therapy; 0.2, 0.5 and 0.8 correspond to 55 
small, moderate and large effects). Random-effects models for meta-analyses were applied. 56 
Main Outcomes and Measures: General quality of life and thyroid-related symptoms after a minimum 57 
follow-up of three months. 58 
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Results: Overall, 21 of 3,088 initially identified publications met the inclusion criteria with 2,192 adults 59 
randomized. After treatment (range 3 to 18 months), thyroid hormone therapy was associated with 60 
lowering the mean TSH value into the normal reference range, compared with placebo (range 0.5 to 61 
3.7mU/l vs 4.6 to 14.7mU/l), but was not associated with benefit regarding general quality of life 62 
(n=796, SMD -0.11, 95%CI -0.25 to 0.03, I2=66.7%) and thyroid-related symptoms (n=858, SMD 0.01, 63 
95%CI -0.12 to 0.14, I2=0.0%). Overall, risk of bias was low and the quality of evidence assessed with 64 
the GRADE tool was judged moderate to high.  65 
Conclusion and Relevance: Among non-pregnant adults with subclinical hypothyroidism, the use of 66 
thyroid hormone therapy was not associated with improvements in general quality of life or thyroid-67 
related symptoms. These findings do not support the routine use of thyroid hormone therapy in adults 68 
with subclinical hypothyroidism. 69 
 70 
Registration:  The study protocol was registered on PROSPERO (CRD42017055536).  71 
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Introduction 72 
Subclinical hypothyroidism, defined as elevated Thyroid-stimulating hormone (TSH) in combination 73 
with a normal free thyroxine (fT4),1 is common.2,3 According to the NHANES III report,4 an estimated 74 
13 million people have subclinical hypothyroidism in the United States. The prevalence is higher in 75 
women and in older people.2,3 Subclinical hypothyroidism is often treated with thyroid hormones 76 
(levothyroxine),5 particularly when it co-occurs with symptoms potentially attributable to 77 
hypothyroidism such as tiredness, constipation, and unexplained weight gain.5  78 
Relatively limited evidence exists from randomized clinical trials (RCTs) to guide therapy of subclinical 79 
hypothyroidism. Systematic reviews have been inconclusive and clinical practice guidelines have 80 
varied regarding recommendations for managing subclinical hypothyroidism.6-10 Two large randomized 81 
trials of levothyroxine therapy in patients with subclinical hypothyroidism were recently completed.11,12   82 
This meta-analysis and systematic review incorporates recent trials and evaluated whether thyroid 83 
hormone therapy was associated with improved symptoms and other benefits in non-pregnant adults 84 
with subclinical hypothyroidism. 85 
Methods 86 
We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 87 
statement13 and published the protocol of this systematic review on PROSPERO (CRD42017055536). 88 
Eligibility criteria, literature search and study selection 89 
We considered randomized trials that included non-pregnant adults with subclinical hypothyroidism. 90 
Subclinical hypothyroidism was defined as TSH above the reference range in combination with an fT4 91 
within the reference range (according to center-specific reference ranges). The intervention had to 92 
consist of thyroid hormone therapy (either triiodothyronine (T3), thyroxine (T4) or a combination of 93 
both) for at least one month, with a minimum follow-up of three months. The control group had to 94 
receive either placebo or no therapy. In order to be included, studies had to report quantitative data for 95 
at least one of the study’s primary or secondary outcomes: general quality of life, thyroid-related 96 
quality of life/hypothyroid symptoms, depressive symptoms, fatigue/tiredness, cognitive function, pain, 97 
muscle strength, blood pressure, body-mass index, cardiovascular events (myocardial infarction, 98 
stroke, revascularization), mortality; or side effects (hyperthyroidism due to overdosing). Data had to 99 
be reported with effect estimates and measures of precision (standard deviations or standard errors). 100 
The primary outcomes were general quality of life and thyroid-related quality of life/hypothyroid 101 
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symptoms, whereas depressive symptoms, fatigue/tiredness, cognitive function, pain, muscle 102 
strength, blood pressure, body-mass index, cardiovascular events (myocardial infarction, stroke, 103 
revascularization), mortality and side effects (hyperthyroidism due to overdosing) were secondary 104 
outcomes. Studies that only included patients with subclinical hypothyroidism in combination with 105 
another specific condition (e.g. patients with diabetic nephropathy and subclinical hypothyroidism) 106 
were excluded, because this type of study population is not representative of most patients with 107 
subclinical hypothyroidism. We excluded studies that exclusively enrolled pregnant women and/or  108 
women who wanted to become pregnant. Pseudorandomization (pre-post comparisons for example) 109 
did not qualify for inclusion. 110 
We searched MEDLINE, EMBASE, Web of Science, COCHRANE Library, CENTRAL, Emcare and 111 
Academic Search Premier from inception until July 4, 2018 in cooperation with a trained librarian. 112 
Search terms were adapted according to the syntax of each specific database, and no language 113 
restrictions were applied. We searched trial registries (clinicaltrials.gov) for upcoming (and not yet 114 
published) trials on this research topic and asked authors for the status of the trial if not published yet. 115 
We screened references of key articles for additional potentially relevant articles. Details of the search 116 
strategy are presented in the Appendix. 117 
Two researchers (MS, MDM) evaluated eligibility independently, based on titles and abstracts of all 118 
studies retrieved in the electronic search. Studies not excluded in this first step were independently 119 
assessed for inclusion after full-text evaluation by two reviewers (MF, MS). We manually screened 120 
bibliographies of the included studies as well as guidelines and major reviews for additional studies. 121 
Discrepancies were resolved by consensus among the study team. 122 
Data extraction and risk of bias assessment 123 
A standard data extraction form was used, adapted from a template suggested by Cochrane (see 124 
Appendix).14 Two researchers (MS, EM) independently extracted bibliographic details, funding source, 125 
eligibility criteria, information about the study population and setting, study design, risk of bias, 126 
intervention/control intervention, results, and independently evaluated the quality of evidence (GRADE 127 
tool).15 In case a study reported more than one outcome measure for a specific outcome domain (e.g. 128 
more than one cognition test to assess cognitive function), we chose the most relevant measure, 129 
based on how broad a domain was assessed and international usage (by consensus among the study 130 
team). As an example, Parle and colleagues reported five different cognition tests.16 We analyzed 131 
results from the Mini-Mental State Examination (MMSE) because it is used worldwide and because it 132 
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is a broader assessment of cognitive function than alternative tests, such as the Trail Making Test. 133 
When a study mentioned an outcome of interest without providing estimates, we contacted the author 134 
for the data (e.g. the study reported no difference in body-mass index between the intervention and 135 
the control group without providing data on mean differences and standard deviations). If studies 136 
reported results for an outcome at multiple time points during the intervention (e.g. body mass index at 137 
6 and 12 months), only the most recent measurement was used in statistical analyses. Data were 138 
extracted in duplicate by two independent reviewers (MS, EM), and differences were resolved by 139 
consensus. 140 
Statistical analyses 141 
Study results were presented separately for each outcome, with estimates as reported in the original 142 
publication and transformed into standardized mean differences (SMD) when different scales were 143 
used for the same outcome domain. We coded SMDs such that positive values indicated benefit of 144 
thyroid hormone therapy, with 0.2, 0.5 and 0.8 corresponding to small, moderate and large effects.17 In 145 
contrast, for body-mass index and blood pressure, negative values indicated benefit of thyroid 146 
hormone therapy. For estimations of treatment effects, we used mean values and their standard 147 
deviations at end of treatment in both groups, assuming balanced baseline values due to the 148 
randomised designs. 149 
For outcomes where studies reported treatment effects at different time points, we only included the 150 
estimate at the most recent follow-up time point, thereby avoiding counting a study twice in a formal 151 
meta-analysis. Overall results were calculated using random effects models, unless less than five 152 
studies were included for a meta-analysis, as in this case the between-study variance cannot be 153 
estimated reliably and a fixed effect analysis was performed. For better clinical interpretation, overall 154 
SMDs were also back-transformed to one original scale according to a method proposed by the 155 
Cochrane Collaboration,17 for general quality of life, thyroid-related quality of life/hypothyroid 156 
symptoms, depressive symptoms, cognitive function and muscle strength. Heterogeneity was 157 
assessed visually with forest plots and quantified with I2 (0-40%, 40-75% and >75% for “low”, 158 
“moderate” and “high”, respectively). If substantial heterogeneity existed and a sufficient number of 159 
publications was available (n=10), we aimed to explore potential sources of heterogeneity in protocol 160 
pre-specified subgroup analyses (e.g. restricting the analysis to high-quality studies). In addition, a 161 
post-hoc sensitivity analysis was performed with the aim to evaluate heterogeneity after excluding 162 
studies showing statistically significant benefit of placebo treatment. In case of a sufficient number of 163 
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publications (n=10), publication bias would be assessed via funnel plots (visually), and more formally 164 
with the Egger test.18 Statistical significance was tested 2-sided, and P-values of <0.05 were judged 165 
statistically significant. All analyses were conducted with Stata, release 14. 166 
Results 167 
The systematic literature search retrieved 3,086 studies, and two additional studies were retrieved 168 
after searching references of key articles. After removing duplicates (1,438), two reviewers (MS, MDM) 169 
independently screened 1,650 unique articles for potential eligibility based on title and abstract. Forty-170 
nine potentially eligible studies were evaluated in full-text independently by two reviewers (MF, MS). 171 
Among these, 25 studies did not meet the inclusion criteria. In addition, three studies would have met 172 
the inclusion criteria but did not present the data in a manner to be included in the meta-analysis.19-21 173 
For two of these articles, the authors indicated that data were not available anymore.19,20 One author 174 
could not be reached (eTable 1 for excluded studies).21 Finally, 21 studies met the inclusion criteria 175 
(Flow chart depicted in eFigure 1). Among the 21 studies, a total of 2,192 adults were randomized 176 
(Table 1 for included studies). The study size ranged from 20 to 737 participants; the mean age 177 
ranged from 32 to 74 years, the proportion of women ranged from 46% to 100%, and baseline mean 178 
TSH ranged from 4.4 to 12.8mU/l. Two studies (99 participants) had a mean baseline TSH 179 
>10mU/l.22,23 Seven studies provided information about hypothyroid symptoms at baseline and in 180 
these studies the burden of symptoms was mild to moderate (Table 1).12,22-27 In the thyroid hormone 181 
therapy groups, mean TSH at the end of follow-up ranged between 0.5 and 3.7mU/l (eTable 2), 182 
indicating that treatment was associated with normalization of  TSH levels. In contrast, mean TSH in 183 
the placebo/no intervention groups remained elevated at the end of follow-up, ranging from 4.6 to 184 
14.7mU/l (eTable 2). The duration of the intervention (thyroid hormone therapy or placebo/no therapy) 185 
ranged from between 3 and 18 months. Three studies compared thyroid hormone therapy to no 186 
intervention and the other studies compared thyroid hormone therapy to placebo,11,28,29 Two studies 187 
were supported by industry (Table 1).22,30  188 
 189 
Thyroid hormone therapy was not associated with benefit for either of the two primary outcomes: Four 190 
studies including 796 participants evaluated general quality of life (SMD -0.11, 95%CI -0.25 to 0.03, I2 191 
66.7%; Figure 1).12,26,27,31 It is estimated that on the EQ-5D scale (range -0.59 to 1.00, higher scores 192 
indicate better quality of life), this SMD would represent a difference of 0.02 (95%CI -0.01 to 0.05) in 193 
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favor of placebo. Four studies including 858 participants evaluated thyroid-related quality of 194 
life/hypothyroid symptoms (SMD 0.01, 95%CI -0.12 to 0.14, I2 0.0%; Figure 1).12,22,31,32 It is estimated 195 
that on the ThyPRO Hypothyroid Symptoms Score (range 0 to 100, higher scores indicate more 196 
hypothyroid symptoms), this SMD would represent a difference of 0.18 (95%CI -2.10 to 2.45) in favor 197 
of levothyroxine. Similarly, thyroid hormone therapy was not associated with benefit regarding the 198 
secondary outcomes: depressive symptoms (four studies, 278 participants, SMD -0.10, 95%CI -0.34 199 
to 0.13, I2 0.0%; Figure 1),16,24,26,31 on the Hospital Anxiety and Depression Scale (range 0 to 21, 200 
higher scores indicate worse depressive symptoms), this SMD would represent a difference of 0.28 201 
(95%CI -0.36 to 0.95) in favor of placebo; cognitive function (four studies, 859 participants, SMD 0.09, 202 
95%CI -0.05 to 0.22, I2 14.7%; Figure 2),12,16,25,26 on the Letter-digit coding test scale (range 0 or 203 
higher (no upper limit), higher scores indicate better cognitive function), this SMD would represent a 204 
difference of 1.01 (95%CI -0.56 to 2.46) in favor of levothyroxine; muscle strength (two studies, 695 205 
participants, SMD 0.1, 95%CI -0.1 to 0.2, I2 0.0%; eTable 4),12,31 in handgrip strength (in kg), this SMD 206 
would represent a difference of 1.12 (95%CI -1.12 to 2.24) in favor of levothyroxine; systolic blood 207 
pressure (eight studies, 1,372 participants, -0.7mmHg, 95%CI -2.6 to 1.2, I2 0.0%; Figure 3),11,12,29,32-36 208 
or body-mass index (15 studies, 1,633 participants, 0.2kg/m2, 95%CI -0.4 to 0.8, I2 45.5%; Figure 209 
4).11,12,23,27-30,32-39 Only the TRUST trial (the largest included study, with 737 participants randomized) 210 
evaluated fatigue/tiredness, cardiovascular events, mortality, and side effects.12 No beneficial or 211 
harmful association between thyroid hormone therapy and these outcomes was reported (Figure 1 & 212 
eTable 2 & 4). No study included pain as an outcome. Detailed results were summarized in eTable 2 & 213 
4. Subgroup analyses were not performed, beacuse the number of studies for a single outcome was 214 
too small and/or there was low to moderate heterogeneity such that no exploration was indicated. As 215 
the meta-analyses for general quality of life and body-mass index showed moderate heterogeneity 216 
(I2=66.7% and I2=45.5%, respectively), post-hoc sensitivity analyses were performed, excluding 217 
studies showing statistically significant benefit of placebo.23,27,30 Results remained similar, but 218 
heterogeneity was lower (general quality of life SMD -0.08, 95%CI -0.22 to 0.06, I2 34.7%; body-mass 219 
index -0.2kg/m2, 95%CI -0.6 to 0.2, I2 1.6%).Further, we did not formally assess publication bias. 220 
Based on the negative results, there was no indication that positive studies were published while 221 
negative studies remained unpublished. 222 
The overall quality of the 21 included studies was good with only nine out of 126 items judged to be at 223 
high risk of bias (eTable 3); two trials had low risk of bias for all critieria,12,22 including the largest and 224 
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most recent one,12 and only one trial, the second largest and second most recent, had a high risk of 225 
bias in three out of six domains.11 Accordingly, the quality of evidence assessed with the GRADE tool 226 
was high regarding the main outcomes general quality of life and thyroid-related symptoms, as well as 227 
regarding muscle strength, blood pressure and body-mass index (eTable 4). The quality of evidence 228 
was moderate for depressive symptoms, fatigue / tiredness, cognitive function and side effects, 229 
whereas it was low for cardiovascular events and mortality (eTable 4). 230 
Discussion 231 
In this systematic review and meta-analysis of RCTs in non-pregnant adults with subclinical 232 
hypothyroidism, thyroid hormone therapy was not associated with benefit regarding general quality of 233 
life, thyroid-related symptoms, depressive symptoms, fatigue/tiredness, cognitive function, muscle 234 
strength, blood pressure and body-mass index. 235 
Compared to prior systematic reviews and meta-analyses, published between 20078 and 20159, this 236 
meta-analysis included two recent randomized trials, which were the largest trials published to date on 237 
this topic.11,12 Overall, the quality of evidence reported here was moderate to high.  Quality of evidence 238 
was high regarding the primary outcomes of this review (general quality of life and thyroid-related 239 
symptoms). Results of this review consistently demonstrated no association of thyroid replacement 240 
therapy with improved outcomes, including a relatively large number of diverse outcomes.  Most 241 
outcomes, except cardiovascular events and mortality, had narrow confidence intervals. In addition, 242 
this meta-analysis focused on patient-centered outcomes such as quality of life and fatigue, which are 243 
the most common symptoms that prompt therapy in general practice.40  244 
Although current guidelines are, at first sight, cautious with treatment recommendations, more than 245 
90% of persons with subclinical hypothyroidism and a TSH <10mU/l would actually qualify for 246 
treatment. 6,10,41 However, results of this meta-analysis are not consistent with these guideline 247 
recommendations. In addition to absence of an association of thyroid hormone therapy with improved 248 
outcomes, thyroid hormone therapy is associated with side effects when overtreatment occurs.5,42,43 249 
 250 
Limitations 251 
This study has several limitations. First, the RCTs included in this meta-analysis used different 252 
questionnaires and/or tests for a given outcome in combination with different treatment durations (e.g. 253 
four different cognitive tests in the four studies examining cognitive function, with treatment durations 254 
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ranging from three to 18 months). However, little heterogeneity across the study results was observed, 255 
except for general quality of life and body-mass index. For these outcomes, heterogeneity resulted 256 
from three studies that showed a statistically significant benefit of placebo.23,27,30 After excluding these 257 
studies in post-hoc sensitivity analyses, thyroid hormone therapy remained  unassociated with benefit 258 
for general quality of life and body-mass index, but heterogeneity was lower. Therefore, it seems 259 
unlikely that this meta-analysis misses a potential beneficial association between thyroid hormone 260 
therapy and any outcome analyzed due to inappropriate pooling of overly heterogeneous studies. 261 
Second, only one RCT reported on major adverse cardiovascular events. Therefore, definitive 262 
evidence is lacking regarding the association of therapy for subclinical hypothyroidism with reduced 263 
cardiovascular event rates.12 Third, RCTs that reported results only qualitatively were excluded from 264 
analyses. Fourth, mean TSH values at baseline were <7.0mU/l in 11 out of 21 included RCTs, and 265 
only two RCTs examined participants with a mean baseline TSH >10mU/l.22,23 Therefore, the current 266 
findings may not be generalizable to people with subclinical hypothyroidism and a TSH >10mU/l. Fifth, 267 
the highest mean age in the included studies was 74 years.12,16 Therefore, these results may not be 268 
generalizable to people older than 80 years. Sixth, only seven of 21 trials (33%) reported hypothyroid 269 
symptoms at baseline, and the burden of symptoms was mild to moderate in these trials. The other 14 270 
trials did not describe symptoms at baseline. It is possible that the subgroup of people with subclinical 271 
hypothyroidism and a high burden of symptoms would still benefit from treatment. Seventh, patients 272 
with subclinical hypothyroidism and “severe” symptoms of hypothyroidism may be underrepresented in 273 
clinical trials because they  may be treated immediately with levothyroxine and are not included in 274 
clinical trials.44 Therefore, results reported here  may not be generalizable to patients with subclinical 275 
hypothyroidism who have severe symptoms. Eighth, two RCTs (n=831) included participants with a 276 
mean age >65 years.12,16 Their mean TSH level at baseline was between 6.0 and 7.0mU/l. Given the 277 
possibility that the upper TSH reference limit may increase with age,45 the two studies may have 278 
included older individuals with mildly elevated TSH levels who do not represent subclinical 279 
hypothyroidism, although current international guidelines do not use different TSH levels according to 280 
age to define subclinical hypothyroidism.6,10,46 However, this phenomenon may have biased the results 281 
towards the null. Ninth, it is possible that thyroid hormone therapy is associated with benefit regarding 282 
outcomes that were not examined in this meta-analysis (e.g. carotid intima media thickness, various 283 
lipid fractions, etc.). Tenth, it is possible that treatment of subclinical hypothyroidism may be beneficial 284 
in study populations not included in these analyses (e.g. patients with subclinical hypothyroidism and 285 
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renal impairment). Eleventh, the largest RCT to date12 contributed substantially to the results of this 286 
meta-analysis because of the large sample size relative to the other trials (737 of 2,192 participants 287 
(33.6%)). However, the mean age of participants in the largest trial was 74 years, while the mean age 288 
of participants in the studies included here ranged from 32 to 74 years.   289 
 290 
Conclusions 291 
Among non-pregnant adults with subclinical hypothyroidism, the use of thyroid hormone therapy was 292 
not associated with improvements in general quality of life or thyroid-related symptoms. These findings 293 
do not support the routine use of thyroid hormone therapy in adults with subclinical hypothyroidism. 294 
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Table 1: Characteristics of 21 included randomized clinical trials on thyroid hormone therapy for subclinical hypothyroidism in adults 
 
Author, y Country 
Funding 
source 
Definition of SCH n 
Mean 
age in 
years 
(SD) 
n women 
(%) 
Intervention Control 
Planned 
follow-up 
duration [in 
months] 
Outcomea 
Hypothyroid 
symptoms at 
baseline [Intervention 
vs Control (SD)] 
Stott,12 2017 
Netherlands, 
Switzerland, 
UK, Ireland 
Non-
industry 
TSH 4.6-19.99mU/l 
on 2 occasions & 
normal fT4 
737 74 (6.3) 
396 
(54%) 
Levothyroxine Placebo At least 12b  
- ThyPRO 
questionnaire48 
- EQ-5D score49 
- Letter-digit coding test50 
- Handgrip strength 
- Blood pressure 
- BMI 
- Cardiovascular events 
- Mortality 
- Side effects48 
ThyPRO hypothyroid 
symptom score 
17.5 (±18.8) vs 16.9 
(±17.9) 
Zhao,11 2016 China 
Non-
industry 
TSH 4.2 – 10.0mU/l, 
normal fT4 on 2 
occasions 
369 55 (7.6) 
270 
(73%) 
Levothyroxine 
No 
intervention 
15  
- Blood pressure  
- BMI 
nr 
Najafi,24 2015 Iran 
Non-
industry 
TSH >4.5mU/l, 
normal fT4, positive 
TPO-Ab 
60 34 (10.0) 51 (85%) Levothyroxine Placebo 3  - BDI51 
Mean number of 
hypothyroid symptoms 
per participant (range 0 
to 12): 
4.8 (±nr) vs 5.1 (±nr) 
Ersoy,29 2012 Turkey 
Not 
declared 
TSH 5.0 – 10.0mU/l, 
normal fT4 
60 46 (13.1) 58 (97%) Levothyroxine 
No 
intervention 
6 
- Blood pressure 
- BMI 
nr 
Aghili,25 2012 Iran 
Non-
industry 
TSH >4.5mU/l, 
normal fT4, positive 
TPO-Ab 
60 34 (10.8) 51 (85%) Levothyroxine Placebo 3  
- Cognitive function 
(Wechsler memory 
scale52) 
Mean number of 
hypothyroid symptoms 
per participant (range 0 
to 7): 
3.2 (±nr) vs 3.7 (±nr) 
Reuters,31 
2012 
Brazil 
Not 
declared 
TSH >4.0mU/l, 
normal fT4 on 2 
occasions 
71 50 (10.9) 62 (87%) Levothyroxine Placebo 6 
- Zulewski score53 
- SF-36 score54 
- BDI51 
- Quadriceps strength 
Zulewski score 
nr (only change from 
baseline reported) 
Cabral,28 
2011 
Brazil 
Not 
declared 
TSH >4mU/l + 
normal fT4 on 2 
occasions 
32 46 (9.0) 
32 
(100%) 
Levothyroxine 
No 
intervention 
12  - BMIc nr 
Parle,16 2010 UK 
Non-
industry 
TSH >5.5mU/l + 
normal fT4 
94 74 (5.8) 57 (61%) Thyroxine Placebo 12  - HADS55 nr 
17 
 
- Cognitive function 
(MMSE,56  MEAMS,57 
SCOLP,58 Trail making 
test59) 
Nagasaki,36 
2009 
Japan 
Non-
industry 
Increased TSH, 
normal fT3/4 
95 65 (19.3) 
95 
(100%) 
Levothyroxine Placebo 5  
- Blood pressure  
- BMI 
nr 
Teixeira,30 
2008 
Brazil 
Industry 
supported 
TSH >4mU/l + fT4 
normal on ≥2 
occasions 
60 48 (10.5) 57 (95%) Levothyroxine Placebo 12  - BMI nr 
Razvi,32 2007 UK 
Non-
industry 
TSH >4mU/l + 
normal fT4 on ≥2 
occasions 
100 54 (12.6) 82 (82%) Levothyroxine Placebo 3 
- ThyDQoL60 
- Blood pressure 
- BMIc 
ThyDQoL 
nr (only change from 
baseline reported)  
Jorde,26 2006 Norway 
Non-
industry 
TSH 3.5-10mU/l 69 62 (11.9) 32 (46%) Thyroxine Placebo 12  
- GHQ-3061 
- BDI51  
- Composite cognitive 
score26 
Mean number of 
hypothyroid symptoms 
per participant (range 0 
to 19): 
4.0 (±nr) vs 4.0 (±nr) 
Iqbal,37 2006 Norway 
Non-
industry 
TSH 3.5-10mU/l on 2 
occasions, fT3/4 
normal 
64 64 (12.2) 31 (48%) Thyroxine Placebo 12  - BMI nr 
Caraccio,38 
2005 
Italy 
Non-
industry 
TSH >3.6mU/l, 
normal fT3/4 
23 32 (9.6) 21 (91%) Levothyroxine Placebo 6  - BMI nr 
Yazici,35 
2004 
Turkey 
Not 
declared 
Increased TSH, 
normal fT3/4 
45 40 (7.9) 38 (84%) Levothyroxine Placebo 12  
- Blood pressure  
- BMI 
nr 
Monzani,34 
2004 
Italy 
Not 
declared 
TSH >3.6mU/l 45 37 (11.0) 37 (82%) Levothyroxine Placebo 6  
- Blood pressure  
- BMI 
nr 
Kong,27 2002 UK 
Not 
declared 
TSH 5-10mU/l, fT4 
normal 
40 50 (15.2) 
40 
(100%) 
Thyroxine Placebo 6  
- GHQ-3061 
- HADS55 
- BMI 
Overall, 33/40 (83%) 
reported fatigue, 32/40 
(80% reported weight 
gain) 
Caraccio,39 
2002 
Italy 
Non-
industry 
TSH >3.6mU/l on 2 
occasions, positive 
TPO-Ab 
49 35 (9.1) 42 (86%) Levothyroxine Placebo 6  - BMI nr 
Monzani,33 
2001 
Italy 
Not 
declared 
TSH >3.6mU/l for >1 
year, normal fT4 
20 32 (12.1) 18 (90%) Levothyroxine Placebo 6  
- Blood pressure  
- BMI 
nr 
Meier,22 2001 Switzerland 
Non-
industry & 
industry 
supportedd 
TSH >5mU/l on 2 
consecutive blood 
tests, fT4 normal 
66 57 (10.6) 
66 
(100%) 
Levothyroxine Placebo 12 - Billewicz score62 
Billewicz score 
-25.7 (±15.2) vs -28.3 
(±14.1) 
Cooper,23 
1984 
USA 
Non-
industry 
Increased TSH, 
normal fT3/4 
33 54 (10.1) 32 (97%) Levothyroxine Placebo 12  - BMI 
Mean number of 
hypothyroid symptoms 
18 
 
per participant (range 0 
to 6): 
2.1 (±nr) vs 2.4 (±nr) 
Abbreviations: y, Year; SCH, Subclinical hypothyroidism; n, Number of participants; SD, Standard deviation; ThyPRO, Thyroid-related quality-of-life patient-reported outcome 
measure (hypothyroid symptoms (4 items, range 0 to 100, higher scores indicate more hypothyroid symptoms) and tiredness score (7 items)); EQ-5D, Euro quality of life 5 
dimensions questionnaire; Letter-digit coding test (assesses executive cognitive function); BMI, Body-mass index; nr, not reported; BDI, Becks Depression Inventory; TPO-Ab, 
Thyroid peroxidase antibody; SF-36, Short Form (36) Health Survey; HADS, Hospital anxiety and depression scale; MMSE, Mini mental state examination; MEAMS, Middlesex 
elderly assessment of mental state; SCOLP, Speed and capacity of language processing test; ThyDQoL, 18-item underactive thyroid-dependent quality of life; GHQ-30, General 
health questionnaire 30 items; Billewicz score (range -47 to 67, higher scores indicates worse hypothyroid symptoms);. 
a Only relevant outcomes for this systematic review are listed, i.e. outcomes that were included in the study protocol and published on PROSPERO 
b The letter digit coding test was available after 18 months of levothyroxine/placebo intervention, the other outcomes after 12 months. 
c Data obtained through direct communication with author 
d This work was supported by the Swiss Research Foundation and an unconditional research grants from Henning Berlin, Sandoz Research, and Roche Research Foundations 
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Titles and legends for figures 
 
Figure 1 title: Forest plots of randomized clinical trials on levothyroxine therapy in subclinical hypothyroidism, 
showing quality of life and mood-related outcomes 
Figure 1 legend: Mean values of the quality of life / mood-related outcome scales per study group are shown 
in appendix eTable 2. Fixed effect meta-analysis of standardized mean differences; weights are from a fixed 
effect analysis. All effect sizes are standardized. As a rule of thumb for the interpretation, a standardized 
mean difference of 0.2, 0.5 and 0.8 correspond to small, moderate and large clinical effects, respectively.63 
For references to the range of the original scales see Table 1. 
Figure 1 footnote: There is a difference between the number of participants randomized, and the number of 
participants with available outcome data in the studies of Kong,27 Jorde,26 Reuters,31 Stott,12 and Meier22 
(see Table 1 & eTable 2). Of note, the study by Razvi et al is a cross-over study, it included 100 
participants.32  
 
 
Figure 2 title: Forest plot of randomized clinical trials on levothyroxine therapy in subclinical hypothyroidism, 
showing outcomes on cognitive function 
Figure 2 legend: Mean values of the cognition scale per study group are shown in appendix eTable 2. Fixed 
effect meta-analysis of standardized mean differences; weights are from a fixed effect analysis; dashed line 
represents the overall mean effect. All effect sizes are standardized. As a rule of thumb for the interpretation, 
a standardized standardized mean difference of 0.2, 0.5 and 0.8 correspond to small, moderate and large 
clinical effects, respectively.63 For references to the range of the original scales see Table 1. 
Figure 2 footnote: There is a difference between the number of participants randomized, and the number of 
participants with available outcome data in the studies of Jorde,26 and Stott12 (see Table 1 & eTable 2).    
 
 
Figure 3 title: Forest plots of randomized clinical trials on levothyroxine therapy in subclinical hypothyroidism, 
showing outcomes on systolic blood pressure 
Figure 3 legend: Fixed effect meta-analysis of differences in blood pressure (mmHg); weights are from a 
fixed effect analysis; dashed line represents the overall mean effect. 
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Figure 3 footnote: There is a difference between the number of participants randomized, and the number of 
participants with available outcome data in the study of Stott12 (see Table 1 & eTable 2). Of note, the study 
by Razvi et al is a cross-over study, it included 100 participants.32  
 
 
Figure 4 title: Forest plots of randomized clinical trials on levothyroxine therapy in subclinical hypothyroidism, 
showing outcomes on body-mass index 
Figure 4 legend: Random effects meta-analysis of differences in BMI (kg/m2); weights are from a random 
effects analysis; dashed line represents the overall mean effect. 
Figure 4 footnote: There is a difference between the number of participants randomized, and the number of 
participants with available outcome data in the studies of Kong,27 Teixeira,30 and Stott12 (see Table 1 & 
eTable 2). Of note, the study by Razvi et al is a cross-over study, it included 100 participants.32  
